ScreenerHero

HRTX Heron Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · herontx.com
0.3843USD+15.86%Mkt Cap: 72.96M $P/E: —

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap72.96M USD
Enterprise Value169.71M USD
Revenue (TTM)151.18M USD
Gross Profit113.56M USD
Net Income (TTM)-20.20M USD
Revenue/Share0.82 USD
Last Price0.3843 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees128
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.02
PEG—
EV/EBITDA-19.44
EV/Revenue1.12
P/S0.42
P/B10.70
EPS (TTM)-0.16
EPS (Forward)-0.11
52W Range
0.26109% of range1.580
52W High1.580 USD
52W Low0.2610 USD
Profitability
Gross Margin73.31%
Oper. Margin-5.43%
EBITDA Margin-5.78%
Profit Margin-13.04%
ROE-140.90%
ROA-7.89%
Growth
Revenue Growth1.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.59M USD
CapEx (TTM)317.00K USD
FCF Margin-5.85%
FCF Yield-12.11%
Net Debt105.69M USD
Net Debt/EBITDA-12.11
Balance Sheet
Debt/Equity9.81
Current Ratio2.49
Quick Ratio1.44
Book Value/Sh0.03 USD
Cash/Share0.23 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 13, 2014
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)+1721.5%
Target Range5.000 USD – 9.000 USD
5.000+1721.5% to mean9.000
# Analysts3
Ownership
Shares Out.189.85M
Float146.52M
Insiders0.98%
Institutions71.00%
Short Interest
Short Ratio21.3d
Short % Float29.10%
Short % Out.22.85%
Shares Short43.38M
Short (prev mo.)46.74M
Technical
SMA 500.3522 (+9.1%)
SMA 2000.7892 (-51.3%)
Beta1.63
S&P 52W Chg16.45%
Avg Vol (30d)2.46M
Avg Vol (10d)2.37M
Technical Indicators
RSI (14)59.6
MACD-0.0012
MACD Signal-0.0135
MACD Hist.+0.0123
BB Upper0.3793 USD
BB Middle0.3205 USD
BB Lower0.2617 USD
BB Width36.68%
ATR (14)0.0357 USD
Vol Ratio (20d)1.47x